Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RE104 in Adjustment Disorder due to Cancer and Other Medical Illnesses
NCT07002034Phase 2Recruiting
- Sponsor
- Reunion Neuroscience
- Start
- Jul 2025
- Primary completion
- Nov 2026
- Modality
- Prodrugs/Conditional Activator Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of RE104 in adjustment disorder (AD), sponsored by Reunion Neuroscience. Started Jul 2025; status: recruiting.
02
Drugs
RE104
03
Conditions
adjustment disorder (AD)
Beyond the preview
Go deeper on NCT07002034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07002034.